Guilong Tanzhu

Dr. Guilong Tanzhu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
XCXianjing Chu
Xianjing Chu
WTWentao Tian
Wentao Tian
JNJiaoyang Ning
Jiaoyang Ning
GXGang Xiao
Gang Xiao
YZYunqi Zhou
Yunqi Zhou
RZRongrong Zhou
Rongrong Zhou
Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor heterogeneity. Cancer continues to be a significant global disease burden. In the past, surgery, radiotherapy, and chemotherapy were the main cancer treatments. The technology of cancer treatments continues to develop and advance, and the emergence of targeted therapy, and immunotherapy provides more options for patients to a certain extent. However, the limitations of efficacy and treatment resistance are still inevitable. Our review begins with a brief introduction of the historical discoveries, original hypotheses, and pathways that regulate CSCs, such as WNT/β-Catenin, hedgehog, Notch, NF-κB, JAK/STAT, TGF-β, PI3K/AKT, PPAR pathway, and their crosstalk. We focus on the role of CSCs in various therapeutic outcomes and resistance, including how the treatments affect the content of CSCs and the alteration of related molecules, CSCs-mediated therapeutic resistance, and the clinical value of targeting CSCs in patients with refractory, progressed or advanced tumors. In summary, CSCs affect therapeutic efficacy, and the treatment method of targeting CSCs is still difficult to determine. Clarifying regulatory mechanisms and targeting biomarkers of CSCs is currently the mainstream idea.

1 January 2024 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
JNJiaoyang Ning
Jiaoyang Ning
LCLiu Chen
Liu Chen
YZYu Zeng
Yu Zeng
GXGang Xiao
Gang Xiao
WTWentao Tian
Wentao Tian
RZRongrong Zhou
Rongrong Zhou
Radiotherapy (RT) stands as the primary treatment for tumors, but it inevitably causes damage to normal cells. Consequently, radiation injury is a crucial consideration for radiation oncologists during therapy planning. Cell death including apoptosis, autophagy, pyroptosis, ferroptosis, and necroptosis play significant roles in tumor treatment. While previous studies elucidated the induction of apoptosis and autophagy by ionizing radiation (IR), recent attention has shifted to pyroptosis, ferroptosis, and necroptosis, revealing their effects induced by IR. This review aims to summarize the strategies employed by IR, either alone or in combination therapy, to induce pyroptosis, ferroptosis, and necroptosis in radiation injury. Furthermore, we explore their effects and molecular pathways, shedding light on their roles in radiation injury. Finally, we summarize the regulative agents for these three types of cell death and their mechanisms. In summary, optimizing radiation dose, dose rate, and combined treatment plans to minimize radiation damage and enhance the killing effect of RT is a key focus.

9 September 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JNJiaoyang Ning
Jiaoyang Ning
LCLiu Chen
Liu Chen
GXGang Xiao
Gang Xiao
YZYu Zeng
Yu Zeng
WSWen Shi
Wen Shi
RZRongrong Zhou
Rongrong Zhou
Tumor metastasis is the leading cause of mortality among advanced cancer patients. Understanding its mechanisms and treatment strategies is vital for clinical application. Arginine methylation, a post-translational modification catalyzed by protein arginine methyltransferases (PRMTs), is implicated in diverse physiological processes and disease progressions. Previous research has demonstrated PRMTs' involvement in tumor occurrence, progression, and metastasis. This review offers a comprehensive summary of the relationship between PRMTs, prognosis, and metastasis in various cancers. Our focus centers on elucidating the molecular mechanisms through which PRMTs regulate tumor metastasis. We also discuss relevant clinical trials and effective PRMT inhibitors, including chemical compounds, long non-coding RNA (lncRNA), micro-RNA (miRNA), and nanomaterials, for treating tumor metastasis. While a few studies present conflicting results, the overall trajectory suggests that inhibiting arginine methylation exhibits promise in curtailing tumor metastasis across various cancers. Nonetheless, the underlying mechanisms and molecular interactions are diverse. The development of inhibitors targeting arginine methylation, along with the progression of clinical trials, holds substantial potential in the field of tumor metastasis, meriting sustained attention.

24 August 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JNJiaoyang Ning
Jiaoyang Ning
YLYi Luo
Yi Luo
LCLiu Chen
Liu Chen
GXGang Xiao
Gang Xiao
GTGuilong Tanzhu
Guilong Tanzhu
RZRongrong Zhou
Rongrong Zhou
Lung cancer is the leading cause of cancer-related mortality worldwide. A major contributing factor to the poor survival rates in lung cancer is the high prevalence of metastasis at the time of diagnosis. To address this critical issue, it is imperative to investigate the mechanisms underlying lung cancer metastasis. Circular RNAs (circRNAs), a distinct type of ribonucleic acid characterized by their unique circular structure, have been implicated in the progression of various diseases. Recent studies have highlighted the close association between circRNAs and the occurrence and development of lung cancer, particularly in relation to metastasis. In this review, we provide a concise overview of the expression patterns and prognostic significance of circRNAs in lung cancer. Additionally, we summarized the current understanding of the clinical relevance of circRNAs in lung cancer metastasis. Furthermore, we systematically focused on the roles of circRNAs in each step of lung cancer metastasis, reflecting the sequential progression of this process. Notably, circRNAs exhibit dual functionality in lung cancer metastasis, acting both as facilitators and inhibitors of metastatic processes. Given their potential, circRNAs hold promise as novel biomarkers and therapeutic targets for lung cancer metastasis, warranting further investigation.

1 January 2026 in Chinese Journal of Cancer Research
Verified
Journal Article
Closed access
XGXiao Gang
Xiao Gang
NJNing Jiaoyang
Ning Jiaoyang
WSWen Su
Wen Su
CLChen Liu
Chen Liu
WHWen Hao
Wen Hao
RZRongrong Zhou
Rongrong Zhou

5 October 2026 in Respiratory Research
Verified
Journal Article
Open access
PDF file
JNJiaoyang Ning
Jiaoyang Ning
GXGang Xiao
Gang Xiao
SWSu Wen
Su Wen
LCLiu Chen
Liu Chen
CWCe Wang
Ce Wang
RZRongrong Zhou
Rongrong Zhou
FURIN, a proprotein convertase, has been implicated in tumor progression. Nevertheless, how it contributes to lung adenocarcinoma (LUAD) and ferroptosis is